Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH) -- Ignore unavailable to you. Want to Upgrade?

To: tommysdad who wrote (4512)	6/17/1998 1:49:00 PM
From: sam	Read Replies (1) \| Respond to of 6136

The market seems to be valuing AGPH's pipeline at a figure not much exceeding $0.00. So, IMHO, any news that isn't "we killed somebody, made them sicker, or made them see blue" will be viewed as a positive.

To: tommysdad who wrote (4512)	6/17/1998 1:53:00 PM
From: Constant Reader	Respond to of 6136

Considering how sick participants in Phase I trials often are, not making them any sicker is actually a BIG achievement, I think. But I agree in the big scheme of things, and a rational market, this isn't the type of news to send the stock to the moon. Take care, Randy